Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Cronos Group
CRON
Cronos Group
GrowCo Capacity And Global Markets Will Unlock Potential
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
30 Apr 25
Updated
15 Aug 25
9
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
CA$3.63
9.4% undervalued
intrinsic discount
15 Aug
CA$3.29
Loading
1Y
-2.1%
7D
3.5%
Author's Valuation
CA$3.6
9.4% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
CA$3.6
9.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-381m
636m
2014
2017
2020
2023
2025
2026
2028
Revenue US$157.2m
Earnings US$45.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.96%
Pharma revenue growth rate
1.05%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
US$45.54m
Earnings '28
x
26.40x
PE Ratio '28
=
US$1.20b
Market Cap '28
US$1.20b
Market Cap '28
/
384.92m
No. shares '28
=
US$3.12
Share Price '28
US$3.12
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
US$2.62
Fair Value '25
US$2.62
Fair Value '25
Converted to CAD @ 1.3813 USD/CAD Exchange Rate
=
CA$3.62
Fair Value '25